A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial

— LANDSCAPE  

Official title:

Prevalence of ADHD and Health Outcomes in Adult Outpatients With Psychiatric Disorders: a Multi-country, Two-part, Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04943796
• Other study ID #: TAK-489-4004
• Secondary ID: MACS-2020-070101
• Status: Recruiting
• Start date: November 6, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: November 2023
• Source: Takeda
• Contact: Takeda Contact
• Phone: +1-877-825-3327
• Email: medinfoUS[@]takeda.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main aim of the study is to find out how frequently adults with at least one psychiatric condition have ADHD (but have not been diagnosed with ADHD before) and to describe the quality of life of these adults who have been diagnosed with ADHD. To find out how often ADHD is not diagnosed in these adults could provide awareness about this condition and could help to improve preventing underdiagnosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 576
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Part I:

• Adult greater than or equal to (>=)18 years of age or Canadian adult >=19 years of age

• Ability to consent, as judged by the study investigator

• Diagnosis of at least one psychiatric disorder of at least 12 months duration, based on International classification of diseases (ICD)-10 codes registered in electronic health records

• Consecutive assessment for ADHD (as per routine clinical practice)

• Able to read and write in the first language of the respective country

Part II

• Inclusion in study Part I

• Diagnosis of ADHD during Part I, according to routine diagnostic procedure and algorithms

• Anticipated availability for being followed over 9 months

Exclusion criteria:

Part I:

• Diagnosis of any of the following at any time prior to signing informed consent:

schizoaffective disorder, intellectual disability, or other cognitive disorders

• Occurrence of any of the following events within the 6 months prior to signing consent: psychotic episodes, acute intoxication, or psychotropic drug withdrawal syndrome.

• Diagnosis of ADHD at any time before study inclusion

• Serious and unstable medical condition (severe disease that limits survival to 1 year)

• Participation in a clinical interventional trial in the 12 months prior signing consent

Part II:

• Participant being followed-up for ADHD in a different site

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder (ADHD)

Locations

Country	Name	City	State
Canada	Pacific Coast Recovery Care	Burnaby	British Columbia
Canada	Regina Mental Wellness Clinic	Regina	Saskatchewan
Germany	Asklepios Klinikum Hamburg	Hamburg
Spain	Hospital Vall d'Hebron	Barcelona
Spain	Clínica Dr. Quintero	Madrid
Sweden	Psykiatrisk klinik Umeå	Umeå

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

Canada,  Germany,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part I: Percentage of Participants With Positive or Negative ADHD Diagnosis	Percentage of participants with positive or negative ADHD diagnosis will be reported.	At baseline
Primary	Part II: Change From Baseline in Quality of Life- questionnaire (AAQoL) by Overall Psychological/Psychiatric Clinical Management	AAQoL (32) is an instrument designed to evaluate the quality of life in ADHD adult participants It has 29 items organized in four domains: Life Productivity (11 items); Psychological Health (6 items), Life Outlook (7 items) and Relationships (5 items). Each item is rated with a five-point Likert scale ranging from 1= Not at all/Never to 5=Extremely/Very Often. Total and domain-specific scores are computed by reversing scores for all items, except those in the Life Outlook domain; transforming all item scores to a 0 to100 point scale (1=0; 2=25; 3=50; 4=75; 5=100); and summing the item scores and dividing by them by item count. Total score ranges from 0 to 100 with higher score representing better quality of life. Change from baseline in AAQoL by overall psychological/psychiatric clinical management will be reported.	Baseline, 3 Month and 9-Month of follow-up
Primary	Part II: Change From Baseline in AAQoL by ADHD-Specific Clinical Management	AAQoL (32) is an instrument designed to evaluate the quality of life in ADHD adult participants It has 29 items organized in four domains: Life Productivity (11 items); Psychological Health (6 items), Life Outlook (7 items) and Relationships (5 items). Each item is rated with a five-point Likert scale ranging from 1= Not at all/Never to 5=Extremely/Very Often. Total and domain-specific scores are computed by reversing scores for all items, except those in the Life Outlook domain; transforming all item scores to a 0 to100 point scale (1=0; 2=25; 3=50; 4=75; 5=100); and summing the item scores and dividing by them by item count. Total score ranges from 0 to 100 with higher score representing better quality of life. Change from baseline in AAQoL by ADHD-Specific Clinical Management will be reported.	Baseline, 3-month, and 9-month follow up
Secondary	Part I: Percentage of Participants With Confirmed Diagnosis of ADHD Based on Adult ADHD Self-Reporting Scale (ASRS)	ASRS is designed to evaluate for severity of symptoms as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). ASRS is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. The minimum score to qualify for study inclusion is 8 (i.e. 4 or more "symptom-positive" answers), and the maximum possible score is 72. The higher the score, the more indicative of higher severity of ADHD symptoms. Each column is used to describe the severity of the individuals symptoms based on the questions asked. Each participant is asked to make a mark within one column for each question that best describes their answer. Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on adult ASRS will be reported.	At baseline
Secondary	Part I: Percentage of Participants With Confirmed Diagnosis of ADHD Based on Diagnostic Interview for Adult ADHD (DIVA 5.0)	DIVA 5.0 is a structured diagnostic interview for Adult ADHD, and is based on the criteria for ADHD in DSM-5. Whenever possible the DIVA should be completed with adults in the presence of a partner and/or family member, to enable retrospective and collateral information to be ascertained at the same time. The DIVA usually takes around one and a half hours to complete. The DIVA only asks about the core symptoms of ADHD required to make the DSM-IV diagnosis of ADHD, and does not ask about other co-occurring psychiatric symptoms, syndromes or disorders. In this study, participant will be interviewed using DIVA only if scores in ASRS showed positive diagnosis of ADHD.; Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on DIVA 5.0 will be reported.	At baseline
Secondary	Part I: Percentage of Participants With Confirmed Diagnosis of ADHD Based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5)	DSM-5 confirm the diagnosis of ADHD if meeting all of the following criteria: (i) having five out of nine ADHD inattention and/or hyperactivity/impulsivity symptoms for the last 6 months or more; (ii) having several symptoms before the 12 years of age; (iii) having several symptoms in at least two settings (e.g., at home or work; and with friends or family members); (iv) having symptoms interfering with quality of social, academic, or occupational functioning; and (v) having symptoms that do not occur exclusively during the course of a psychotic disorder and are not better explained by another mental disorder.; Percentage of participants with confirmed diagnosis of ADHD in participants with psychiatric disorder based on DSM-5 will be reported.	At baseline
Secondary	Part II: Number of Modalities for Non-ADHD Psychiatric/Psychological clinical management	Number of modalities for non-ADHD psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Type of Treatment Given to Participants with ADHD for Non-ADHD Psychiatric/Psychological Clinical Management	Type of treatment given to participants with ADHD for non-ADHD psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Duration of Treatment for Non-ADHD Psychiatric/Psychological Clinical Management	Duration of treatment for non-ADHD psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Number of Modalities for ADHD-specific Psychiatric/Psychological Clinical Management	Number of modalities for ADHD-specific psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Type of Treatment Given to Participants with ADHD for ADHD-Specific Overall Psychiatric/Psychological Clinical Management	Type of treatment given to participants with ADHD for ADHD-specific overall psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Duration of Treatment for ADHD-Specific Psychiatric/Psychological Clinical Management	Duration of treatment for ADHD-specific psychiatric/psychological clinical management will be assessed.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Change From Baseline in Functional Assessment Short Test (FAST) Score	FAST is a brief instrument designed to assess the main functioning problems experienced by psychiatric participants, particularly bipolar participants. It comprises 24 items that assess impairment or disability in six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time. The scale used to evaluate functionality is the FAST Scale, the minimum value being 0 and maximum value of 72, domain scores are scaled in a negative direction (i.e. lower scores denote higher functionality).	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Change From Baseline in Clinical Global Impressions Scale- Severity of Illness (CGI-S)	CGI-S is a 7-point scale to rate the participant's severity of illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis by means of one question: Considering your total clinical experience with this particular population, how mentally ill is the participant at this time which is rated on the following seven-point scale with range from 1 to 7 were: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Change From Baseline in Clinical Global Impressions Scale- Improvement (CGI-I) Score	CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention: Compared to the participant's condition at admission to the project [prior to medication initiation], this participant's condition ranges from 1 to 7 were: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Change From Baseline in Health Resource Utilization (HRU)	Utilization of health resources by the study population during the 12 months prior ADHD assessment in the total sample and according to the diagnosis will be assessed at baseline, 3-months and 9 months follow up.	Baseline, 3 Month and 9-Month of follow-up
Secondary	Part II: Functionality Level and Quality of Life by ADHD-Specific Clinical Management	Continues variables (e.g., age, functionality scores, quality of life scores, number of previous visits to the hospital) and categorical variables (e.g., sex, clinical characteristics, psychiatric disorders, ADHD warning signs, treatments, previous tests) will be described in the total sample and according to confirmed/no confirmed ADHD; and will be compared using T-test or ANOVA test (continues variables) and Chi squared test (categorical variables).	Baseline, 3-month, and 9-month follow up

External Links

•   To obtain more information on the study, click here/on this link